AyuVis Research
Business Services · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1120 South Fwy Ste 123E, Fort Worth, Tex...Phone Number
(817) 554-8148Website
www.ayuvis.comRevenue
<$5 MillionIndustry
About AyuVis Research
AyuVis Research is focused on developing a new class of immunotherapies aimed at treating complicated respiratory infections such as Bronchopulmonary Dysplasia (BPD) and Pulmonary Alveolar Proteinosis (PAP), particularly in patients with ARDS induced by COVID-19. Their innovative small molecules are designed to enhance the body's immune response without causing immunosuppression or contributing to drug resistance. The company aims to provide affordable and accessible treatments for ICU patients facing life-threatening inflammation and infections. With promising preclinical data and plans for human clinical trials, AyuVis is positioned to transform the landscape of therapies for severe respiratory conditions.Explore more
AyuVis Research Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to AyuVis Research
Compare insights from companies similar to AyuVis Research, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AyuVis Research Tech Stack
A closer look at the technologies used by AyuVis Research
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AyuVis Research
Sign Up For FreeTo access detailed company insights
AyuVis Research is focused on developing a new class of immunotherapies aimed at treating complicated respiratory infections such as Bronchopulmonary Dysplasia (BPD) and Pulmonary Alveolar Proteinosis (PAP), particularly in patients with ARDS induced by COVID-19. Their innovative small molecules are designed to enhance the body's immune response wi... Read More
